CRISPR / Cas9 as a healing perspective for Diabetes mellitus type 1
DOI:
https://doi.org/10.33448/rsd-v9i12.10709Keywords:
CRISPR / Cas9; Immunology of DM1; Treatment.Abstract
Introduction: Diabetes mellitus type 1 (DM1) is considered an autoimmune, chronic, multifactorial disease, which involves the progressive destruction of β cells in pancreatic islets, which are responsible for the production of insulin, thus resulting in the loss of production and secretion of same. It is estimated that more than 30 thousand Brazilians suffer from this pathology. Three mechanisms are responsible for the destruction of these cells: genetic susceptibility, autoimmunity and environmental factors. In this sense, the objective of this study was to carry out a survey about the main perspectives of cure of this disease using the CRISPR / Cas9 system. Methodology: This is a bibliographic review with searches in national and international electronic databases in Portuguese and English. Results: Since this pathology still has no cure, only treatment, the CRISPR / Cas9 system emerges as a promising therapy, as well as therapy with pluripotent menenchymal stem cells (MSC), which have the functionality, mainly, of repair and survival of β cells from pancreatic islets, MSCs have the ability to modify the microenvironment of the areas of pancreatic injury, canceling the autoimmune destruction against β cells and can restore the patient's normoglycemia. Conclusion: Bearing in mind that this is a pathology of a genetic nature, CRISPR / Cas9 associated with therapy with pluripotent mensenchymal cells has been shown to be a versatile and effective tool in the treatment of DM1. However, there is a need for further research capable of inducing strategies for the improvement of genetic alterations and greater efficiency of the therapeutic effect.
References
Atkinson, M. A. (2012). The pathogenesis and natural history of type 1 diabetes. Cold Spring Harbor perspectives in medicine, 2(11), a007641.
Van Belle, T. L., Coppieters, K. T., & Von Herrath, M. G. (2011). Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiological reviews, 91(1), 79-118.
Brandstetter, T. Dissecting the Role of the IFIH1 Locus in Type 1 Diabetes using Genome Editing.
Chhabra, P., & Brayman, K. L. (2013). Stem cell therapy to cure type 1 diabetes: from hype to hope. Stem cells translational medicine, 2(5), 328-336.
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., & Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science, 339(6121), 819-823.
Geraldo, G. R., & Silva, S. C. C. D. (2017). SISTEMA CRISPR-Cas COMO FERRAMENTA PARA PESQUISAS EM DIABETES: UMA REVISÃO.
Gregory J. M., Moore D. J., Simmons J. H. Type 1 diabetes mellitus. Pediatr Rev. 2013 May;34(5):203-15. doi: 10.1542/pir.34-5-203.
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. science, 337(6096), 816-821.
Lehuen, A., Diana, J., Zaccone, P., & Cooke, A. (2010). Immune cell crosstalk in type 1 diabetes. Nature Reviews Immunology, 10(7), 501-513.
Lucena, J. B. S. (2007). Diabetes mellitus tipo 1 e tipo 2. Monografia]. São Paulo (SP): Centro Universitário das Faculdades Metropolitanas Unidas.
Marraffini, L. A., & Sontheimer, E. J. (2010). CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. Nature Reviews Genetics, 11(3), 181-190.
Nodari, R. O., Guerra, M. P., de Mesuita Dantas, A. C., Stefenon, V. M., & Klabunde, G. H. F. (2016). FIT 5806-BIOTECNOLOGIA.
Oliveira, J. E. P. D., & Vencio, S. (2017). Diretrizes da Sociedade Brasileira de Diabetes 2017-2018. São Paulo: Editora Clannad, 91.
Sociedade Brasileira de Diabetes. (2019). Diretrizes da Sociedade Brasileira de Diabetes 2019-2020.
Sesterheim, P. A. T. R. Í. C. I. A., Saitovitch, D. A. V. I. D., & Staub, H. L. (2007). Diabetes mellitus tipo 1: multifatores que conferem suscetibilidade à patogenia auto-imune. Scientia medica, 17(4), 212-217.
Silva, H. P. V. D. (2013). Estudo dos genes do complexo do antígeno leucocitário humano (hla) associados à susceptibilidade ao diabetes mellitus tipo 1 (Master's thesis, Universidade Federal do Rio Grande do Norte).
de Sousa, A. A., Albernaz, A. C., & Sobrinho, H. M. R. (2016). Diabetes Melito tipo 1 autoimune: aspectos imunológicos. Universitas: Ciências da Saúde, 14(1), 53-65.
Vasconcelos, M. J. V., & Figueiredo, J. E. F. (2015). Tecnologia CRISPR-Cas para edição genômica. Embrapa Milho e Sorgo-Documentos (INFOTECA-E).
Vieira, G. V., Cecílio, N. T., Arruda, L. M., & Sales, K. U. (2016). Visão geral do mecanismo básico de ação. Introdução à técnica de CRISPR. 1ª edição. Ribeirão Preto, Sociedade Brasileira de Genética, 39-50.
Zhu, Y., Liu, Q., Zhou, Z., & Ikeda, Y. (2017). PDX1, Neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration. Stem cell research & therapy, 8(1), 1-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Milena Roberta Freire da Silva; Karolayne Silva Souza; Milena Danda Vasconcelos Santos; Kaleen Massari Leite; Jaqueline dos Santos Silva; Diego Canuto Bispo da Silva; Kleber Ribeiro Fidelis; Rodrigo Reges dos Santos Silva; Graziele dos Santos; Renata Pereira Lima da Silva; Filipe Silva Nunes; Leandro Paes de Brito; Felicson Leonardo Oliveira Oliveira; Maria Betânia Melo de Oliveira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
